Cargando…

Association of Fat Body Mass With Vertebral Fractures in Postmenopausal Women With Early Breast Cancer Undergoing Adjuvant Aromatase Inhibitor Therapy

IMPORTANCE: Aromatase inhibitors induce a profound depletion in serum estrogen levels. Postmenopausal obese women receiving aromatase inhibitor therapy may be at increased risk of bone fractures owing to the detrimental association of adiposity with bone quality and the loss of the protective effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pedersini, Rebecca, Amoroso, Vito, Maffezzoni, Filippo, Gallo, Fabio, Turla, Antonella, Monteverdi, Sara, Ardine, Mara, Ravanelli, Marco, Vassalli, Lucia, Rodella, Filippo, Formenti, Anna Maria, Dalla Volta, Alberto, Simoncini, Edda Lucia, Giustina, Andrea, Maroldi, Roberto, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2019
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6777242/ https://www.ncbi.nlm.nih.gov/pubmed/31560383 http://dx.doi.org/10.1001/jamanetworkopen.2019.11080

Ejemplares similares

The Interaction of Lean Body Mass With Fat Body Mass Is Associated With Vertebral Fracture Prevalence in Women With Early Breast Cancer Undergoing Aromatase Inhibitor Therapy
por: Monteverdi, Sara, et al.
Publicado: (2020)

Changes in eating habits and food preferences in breast cancer patients undergoing adjuvant chemotherapy
por: Pedersini, Rebecca, et al.
Publicado: (2021)

Assessment of DXA derived bone quality indexes and bone geometry parameters in early breast cancer patients: A single center cross-sectional study
por: Pedersini, Rebecca, et al.
Publicado: (2023)

Sleep disturbances and restless legs syndrome in postmenopausal women with early breast cancer given adjuvant aromatase inhibitor therapy
por: Pedersini, Rebecca, et al.
Publicado: (2022)

Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy
por: Pedersini, Rebecca, et al.
Publicado: (2023)

Changes in body composition and lipid profile in prostate cancer patients without bone metastases given Degarelix treatment: the BLADE prospective cohort study
por: Palumbo, Carlotta, et al.
Publicado: (2021)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures
por: Dalla Volta, Alberto, et al.
Publicado: (2020)

A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients
por: Guerini, Andrea Emanuele, et al.
Publicado: (2020)

1693P Accurate triage may be efficacious in selecting patients who could safely continue anticancer therapy during SARS-CoV-2 pandemic
por: Gurizzan, C., et al.
Publicado: (2020)

Prediction of vertebral fractures in cancer patients undergoing hormone deprivation therapies: Reliability of who fracture risk assessment tool (frax) and bone mineral density in real-life clinical practice
por: Mazziotti, Gherardo, et al.
Publicado: (2022)

Accurate Triage of Oncological Patients for Safely Continuing Cancer Therapy During the SARS-CoV-2 Pandemic
por: Gurizzan, Cristina, et al.
Publicado: (2021)

Hypocalcemia: the quest for the cause of a major biochemical feature of COVID-19
por: di Filippo, Luigi, et al.
Publicado: (2020)

Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients
por: Bertelsen, Bjørn-Erik, et al.
Publicado: (2021)

Flying through congested airspaces: imaging of chronic rhinosinusitis
por: Farina, Davide, et al.
Publicado: (2010)

Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006)

Clinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2013)

Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors
por: Hong, Dongsheng, et al.
Publicado: (2017)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Association of adjuvant aromatase inhibitor with cataract risk in postmenopausal women with breast cancer
por: Chen, Han, et al.
Publicado: (2020)

Osteoblastic flare in a patient with advanced gastric cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria
por: Amoroso, Vito, et al.
Publicado: (2007)

Bone Safety Profile of Steroidal Aromatase Inhibitor in Comparison to Nonsteroidal Aromatase Inhibitors in Postmenopausal Women with Breast Cancer: A Network Meta-Analysis
por: Chen, Shanshan, et al.
Publicado: (2022)

Sacituzumab govitecan and radiotherapy in metastatic, triple-negative, and BRCA-mutant breast cancer patient with active brain metastases: A case report
por: di Mauro, Pierluigi, et al.
Publicado: (2023)

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
por: Yates, R. A., et al.
Publicado: (1996)

Effects of steroidal and nonsteroidal aromatase inhibitors on markers of bone turnover in healthy postmenopausal women
por: Goss, Paul E, et al.
Publicado: (2007)

Aromatase inhibitors, efficacy and metabolic risk in the treatment of postmenopausal women with early breast cancer
por: Gonnelli, Stefano, et al.
Publicado: (2008)

Prevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
por: Lomax, Anna J., et al.
Publicado: (2013)

Ovarian mucinous adenocarcinoma with functioning stroma in postmenopausal women: aromatase and SF-1 expressions
por: Hattori, Yuka, et al.
Publicado: (2015)

Survival Benefit of Zoledronic Acid in Postmenopausal Breast Cancer Patients Receiving Aromatase Inhibitors
por: Ahn, Sung Gwe, et al.
Publicado: (2014)

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors
por: Gibb, Fraser W, et al.
Publicado: (2019)

Treatment monitoring of paranasal sinus tumors by magnetic resonance imaging
por: Farina, Davide, et al.
Publicado: (2010)

The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study
por: Lasagna, Angioletta, et al.
Publicado: (2022)

Immune-related adverse events as potential surrogates of immune checkpoint inhibitors’ efficacy: a systematic review and meta-analysis of randomized studies
por: Amoroso, V., et al.
Publicado: (2023)

SAT-389 Clinical and Biochemical Characterization of Risk Factors for Vertebral Fractures in Patients with Hypoparathyroidism
por: Formenti, Anna Maria, et al.
Publicado: (2020)

BS-Net: Learning COVID-19 pneumonia severity on a large chest X-ray dataset
por: Signoroni, Alberto, et al.
Publicado: (2021)

Role of Body Composition in the Prediction of Skeletal Fragility Induced by Hormone Deprivation Therapies in Cancer Patients
por: Dalla Volta, Alberto, et al.
Publicado: (2023)

Aromatase inhibitors as adjuvant therapy for postmenopausal women: a therapeutic advance but many unresolved questions
por: Ligibel, Jennifer A, et al.
Publicado: (2005)

Management of sexual dysfunction in postmenopausal breast cancer patients taking adjuvant aromatase inhibitor therapy
por: Derzko, C., et al.
Publicado: (2007)

Molecular profiling of aromatase inhibitor sensitive and resistant ER+HER2- postmenopausal breast cancers
por: Schuster, Eugene F., et al.
Publicado: (2023)

Diagnostic work-up in obstructive and inflammatory salivary gland disorders
por: Ugga, L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_prqh35ni7tb5il70plg8clvi3p